I am betting/hoping Bydureon getting approved next Jan2012. It is obvious to me exenatide is the best current drug in its class except for the inept crew of Dan Bradbury.
A few years ago this board had a survey to pick the worst biotech CEO of all time. Bradbury received a couple of votes, IIRC.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”